SPRY Stock Tanks Over 23% After-Hours — ARS Pharmaceuticals Reports No New Major Insurance Wins For Neffy
ARS Pharmaceuticals (SPRY) shares fell 23% after-hours as it reported no new major commercial insurance coverage for Neffy effective July 1. The company is in negotiations with payers and secured additional Medicaid coverage. ARS lowered 2026 operating expense guidance to $248M and reaffirmed cash flow break-even target for 2027. Neffy had 120,000 U.S. patients in Q1 and $72.2M in 2025 net sales, 86% of total revenue.
How this was made
The 30-second read
Why it matters
The lack of new commercial coverage and lowered expense guidance suggest short‑term revenue pressure, but Medicaid wins and ongoing negotiations may mitigate long‑term risk.
Market read
The news triggered a sharp after‑hours sell‑off, indicating immediate trading relevance for SPRY holders and short‑term traders.
What to watch
Potential upcoming data on neffy efficacy and patient adoption could improve payer negotiations beyond the disclosed period.
Background
ARS Pharmaceuticals recently launched neffy, a needle‑free epinephrine spray, and has been seeking commercial payer formulary placements.
Ticker impact
After-hours drop of >23% as ARS disclosed no new major commercial insurance coverage for neffy and lowered 2026 operating expense guidance to $248M.
Further downside pressure likely if coverage gaps persist.
The stock already fell sharply; without new payer wins the revenue outlook is constrained, supporting continued sell pressure.
Market effects
Highlights ongoing payer access challenges for biotech allergy therapeutics, may pressure peers with similar reimbursement profiles.
U.S. specialty pharma segment could see modest investor caution.
Limited to U.S. market; no broader macro effect.
Counterpoint
The Medicaid wins could serve as a foothold for broader coverage later, offering a buying opportunity at depressed prices.
Key entities
- companyARS Pharmaceuticals
Developer of neffy nasal spray, ticker SPRY.
